Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunologic Effects of ALK HDM Tablets in HDM-Allergic Rhinitis and Asthma
NCT02596321Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Oct 2015
- Primary completion
- Jun 2016
- Modality
- Allergy Immunotherapy
- Countries
- 2
01
Overview
A Phase 3 trial of House dust mite allergen extract in allergic rhinitis (AR), sponsored by Abbott Laboratories. Started Oct 2015; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02596321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596321.